R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.

Pockros, Paul J

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. [electronic resource] - Hepatology (Baltimore, Md.) Aug 2008 - 385-97 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

1527-3350

10.1002/hep.22357 doi


Adult
Aged
Aged, 80 and over
Alanine Transaminase--blood
Antiviral Agents--administration & dosage
Cytidine--analogs & derivatives
Dose-Response Relationship, Drug
Double-Blind Method
Drug Resistance, Viral
Drug Synergism
Drug Therapy, Combination
Female
Hepacivirus--enzymology
Humans
Interferon alpha-2
Interferon-alpha--adverse effects
Male
Middle Aged
Neutropenia--chemically induced
Nucleosides--administration & dosage
Polyethylene Glycols--adverse effects
Prodrugs--administration & dosage
RNA, Viral--antagonists & inhibitors
Recombinant Proteins
Ribavirin--adverse effects
Treatment Outcome
Viral Load